Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration with Takeda
Shots:
- Egle has achieved the first milestone in its research agreement with Takeda- signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential therapies
- Egle has leveraged its unique bioinformatic & translational capabilities to identify targets
- Following the achievement of the target identification- Egle will receive an R&D milestone payment & equity funding from Takeda
Ref: Businesswire| Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
